Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products

NEWTON, Mass., Apr 17, 2014 (BUSINESS WIRE) — Alcresta®, a leading medical nutrition company developing       innovative enzyme-based products for individuals with unique nutritional needs battling acute conditions or chronic diseases, today announced the       company has signed an agreement with Cystic Fibrosis Foundation Therapeutics (CFFT) to accelerate the development of Alcresta’s       enzyme-based point-of-care products to support the nutritional status of people with cystic fibrosis (CF). CFFT is the nonprofit drug discovery  and development affiliate of the Cystic Fibrosis Foundation. More than 90 percent of people with CF have a compromised pancreas and       need enzyme-based nutritional products to digest and absorb vitamins and  nutrients. To address these challenges, people with compromised  pancreatic or gastrointestinal function, including people with CF, consume nutritional drinks and use tube feedings to supplement their  diet. This agreement allows Alcresta to accelerate the development of  its nutrition technology and advance point-of-care products designed to address the specific needs of the CF population and others with unique nutritional needs by improving absorption of beneficial fatty acids and aiding in overall caloric intake. According to the CF Foundation’s patient data report, a relationship has  been established in CF between good health outcomes and patients’ nutritional levels, reinforcing the...
Source: Cystic Fibrosis Worldwide Blog - Category: Respiratory Medicine Authors: Tags: Research and Discovery Source Type: blogs